Eplerenone and new-onset diabetes in patients with mild heart failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)

European Journal of Heart Failure

Volumn 14, Issue 8, 2012, Pages 909-915

  Preiss, David ^a   Van Veldhuisen, Dirk J ^b   Sattar, Naveed ^a   Krum, Henry ^c   Swedberg, Karl ^d   Shi, Harry ^e   Vincent, John ^e   Pocock, Stuart J ^f   Pitt, Bertram ^g   Zannad, Faiez ^h   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e PFIZER INC   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Chronic heart failure; Diabetes; Eplerenone; Prediction

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO;

ADD ON THERAPY; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; DIABETES MELLITUS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE;

EID: 84864433114     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs067     Document Type: Article

References (25)

1. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-1240.
2. Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, Sattar N. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 2009;32:915-920.
3. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A; COMET investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007;93:968-973.
4. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207.
5. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490.
6. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53.
7. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010;160:915-921.
8. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006;55:1645-1652.
9. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47:1687-1694.
10. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008;51:762-768.
11. Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, Zavos C, Tsarouchas G, Rakitzi P, Slavakis A. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst 2011;12: 498-503.
12. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-622.
13. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
14. Centers for Disease Control and Prevention. Diabetes Data and Trends 2009; available at: http://www.cdc.gov/diabetes/statistics/incidence/fig3.htm (last accessed 2 February 2012)
15. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010;95: 1986-1990.
16. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-3463.
17. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011;4:1239-1249.
18. Heianza Y, Hara S, Arase Y, Saito K, Totsuka K, Tsuji H, Kodama S, Hsieh SD, Yamada N, Kosaka K, Sone H. Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1). Diabetologia 2011;54:762-726.
19. Aksnes TA, Kjeldsen SE, Rostrup M, Storset O, Hua TA, Julius S. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens 2008;22:520-527.
20. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004;53:2855-2860.
21. Fraser A, Harris R, Sattar N, Ebrahim S, Davey SG, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, incident diabetes: the British Women's Heart, Health Study, meta-analysis. Diabetes Care 2009;32:741-750.
22. Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L, Behar S. Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis. Cardiology 2003;100:207-215.
23. Iannello S, Milazzo P, Belfiore F. Animal and human tissue Na,K-ATPase in obesity and diabetes: a new proposed enzyme regulation. Am J Med Sci 2007;333:1-9.
24. Bagrov YY, Manusova NB, Frolova EV, Egorova IA, Kashkin VA, Tapilskaya NI, Fedorova OV, Bagrov AY. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. Preliminary observations and a hypothesis. Pathophysiology 2007;14:147-151.
25. Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 2007;23: 551-558.